Data To Be Presented At EuroTIDES 2006 Conference
BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM), a developer of bioactive peptides, today
announced that Timothy J. Falla, Ph. D, Chief Scientific Officer, will be
presenting results of a new study demonstrating antifungal efficacy of its
novel family of lipo-peptides in a preclinical infection model at IBC's 7th
Annual EuroTIDES 2006 conference on Oligonucleotide, RNAi and Peptide
Technology. The conference will be held at the Radisson SAS in Hamburg,
Germany, on December 4th through the 7th. Dr. Falla's presentation
"Synthetic Lipohexapeptides: A Novel Class of Anti-infective" will take
place on December 5th at 12:20 pm.
Helix BioMedix's lipo-peptide compounds exhibited significant efficacy
both clinically and mycologically in a recent animal study, and leading
investigators have concluded that further evaluation is warranted. The
independent research study was conducted by Mahmoud A. Ghannoum, Ph.D. at
the Center for Medical Mycology, University Hospitals of Cleveland/Case
Western Reserve University.
"This study was a component of our proof of concept evaluation for
these molecules to be used for dermatological application and we are very
pleased with the results," commented Dr. Falla. "Due to the broad spectrum
of activity of this new class of potential anti-infective, the results of
previous bacterial infection models, and the results of this latest study,
we have confidence that there is great potential for addressing a wide
range of pathogen-based dermatological indications in a market that is
estimated at $665 million."
The study involved use of a guinea pig model, which was developed and
used earlier at the Center for Medical Mycology in the pre-clinical
evaluation of terbinafine and itraconazole, the two FDA-approved antifungal
agents currently on the market for treatment of onychomycosis, or fungal
nail infections. The experimental animals were infected with conidia, which
was applied on abraded skin, and then were divided into groups, including
three treatment groups of peptides, an untreated control, vehicle control
and a positive control (terbinafine). Three days after inoculation, animals
were treated topically once daily for a period of seven days. At the end of
treatment, hair samples were removed for mycologic evaluation of fungal
growth at the hair root and clinical assessment was made of the infected
skin area. Test compounds HB 1275 and HB 1148 showed significant efficacy
both clinically and mycologically.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 100,000 unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties
of these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on
the development of selected peptides as topical anti-infectives and in
wound healing. Non- pharmaceutical applications being pursued by Helix
BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care,
plant health, animal health and wide-spectrum biocides. More information
about the company and its proprietary peptides can be found on the
company's website at http://www.helixbiomedix.com.
Contact:
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
Investor Relations: Alison Ziegler of Cameron
Associates, +1-212-554-5469 or alison@cameronassoc.com, for Helix
BioMedix, Inc.
|
